Revealing Activation Mechanism of Alk2 Kinase Mutations in Fibrodysplasia Ossificans Progressiva (FOP)

被引：0
|
作者：
Alsamarah, Abdelaziz [1 ]
Hao, Jijun [2 ]
Luo, Yun [1 ]
机构：
[1] Western Univ Hlth Sci, Pharmaceut Sci, Pomona, CA USA
[2] Western Univ Hlth Sci, Coll Vet Med, Pomona, CA USA
来源：
BIOPHYSICAL JOURNAL | 2016年 / 110卷 / 03期
关键词：
D O I：
10.1016/j.bpj.2015.11.1146
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
1024-Pos
引用
收藏
页码：206A / 206A
页数：1
相关论文
共 50 条
  • [1] Molecular dynamics study of ALK2 kinase mutations in fibrodysplasia ossificans progressiva disorder
    Luo, Yun
    Alsamarah, Abdelaziz
    Hao, Jijun
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [2] Rational design of ALK2 small molecule inhibitors for treatment of fibrodysplasia ossificans progressiva (FOP)
    Luo, Yun
    Alsamarah, Abdelaziz
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [3] Fibrodysplasia ossificans progressiva (FOP)
    Kaplan, FS
    Smith, RM
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (05) : 855 - 855
  • [4] A constitutively activated BMP receptor, ALK2, induces heterotopic bone formation in patients with Fibrodysplasia Ossificans Progressiva (FOP)
    Fukuda, T.
    Kohda, M.
    Kanomata, K.
    Nojima, J.
    Kamizono, J.
    Oda, H.
    Nakayama, K.
    Ohtake, A.
    Miyazono, K.
    Jimi, E.
    Owan, I.
    Okazaki, Y.
    Katagiri, T.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S10 - S10
  • [5] A clinical update on BLU-782, an investigational selective ALK2 inhibitor in development for fibrodysplasia ossificans progressiva (FOP)
    Davis, Alison
    Albayya, Faris
    Lobbardi, Riadh
    Palmer, Michael
    Sherwin, Cori Ann
    Green, Sara
    Stevison, Faith
    Kim, Sean
    Wilkie, Gordon
    Kadambi, Vivek
    Dorsch, Marion
    Boral, Andy
    LaBranche, Timothy
    Hurtt, Mark
    Schwabb, Robert
    Stewart, Rachel
    Lyon, Morgan
    Pauplis, Rachel
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 : 290 - 290
  • [6] Fibrodysplasia (myositis) ossificans progressiva (FOP)
    Ramirez-Gonzalez, Alfredo
    Castaneda-de-la-Fuente, Angelica
    Castro-Cervantes, Vladimir
    Pineda, Carlos
    Sandoval, Hugo
    Hidalgo-Bravo, Alberto
    [J]. CLINICAL RHEUMATOLOGY, 2022, 41 (06) : 1929 - 1930
  • [7] Fibrodysplasia (myositis) ossificans progressiva (FOP)
    Alfredo Ramirez-Gonzalez
    Angelica Castañeda-de-la-Fuente
    Vladimir Castro-Cervantes
    Carlos Pineda
    Hugo Sandoval
    Alberto Hidalgo-Bravo
    [J]. Clinical Rheumatology, 2022, 41 : 1929 - 1930
  • [8] Preclinical Characterization of BCX9250, a Potent Oral Activin receptorlike kinase-2 (ALK2) Inhibitor, for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
    Chen, Xilin
    Cheng, Xiaogang
    Kallogg-Yelder, Debra
    Liu, Qinde
    Muppa, Saritha
    Parker, Cynthia
    Raman, Krishnan
    Kotian, Pravin
    Babu, Yarlagadda
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 96 - 96
  • [9] ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma
    Sekimata, Katsuhiko
    Sato, Tomohiro
    Sakai, Naoki
    [J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 2020, 68 (03) : 194 - 200
  • [10] Structure of the Bone Morphogenetic Protein Receptor ALK2 and Implications for Fibrodysplasia Ossificans Progressiva
    Chaikuad, Apirat
    Alfano, Ivan
    Kerr, Georgina
    Sanvitale, Caroline E.
    Boergermann, Jan H.
    Triffitt, James T.
    von Delft, Frank
    Knapp, Stefan
    Knaus, Petra
    Bullock, Alex N.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (44) : 36990 - 36998
12345